Answers are grounded in this paper and cite their sources.
Background: Biologic therapies have improved outcomes in patients with severe uncontrolled chronic rhinosinusitis with nasal polyps (CRSwNP), but reliable biomarkers predicting treatment response remain unclear. This systematic review and meta-analysis evaluated predictive biomarkers associated with response to biologic therapy. Methods: A systematic review of randomized controlled trials and observational studies evaluating biomarkers of response to biologic therapy in severe uncontrolled CRSwNP was conducted. Data were extracted using a standardized form, and quantitative synthesis was performed where appropriate. Risk of bias was assessed using the Cochrane risk-of-bias 2 tool and the Newcastle–Ottawa Scale. Results: The most frequently investigated predictors of treatment response included blood eosinophil count, serum IgE, tissue eosinophilia, FeNO, and clinical characteristics such as comorbid asthma and NSAID-exacerbated respiratory disease (NSAID-ERD). Biologic therapy consistently improved clinical outcomes; however, evidence supporting any single biomarker as a reliable predictor of treatment response remained inconsistent because of substantial heterogeneity across studies. Conclusions: Current evidence does not support a universally validated predictive biomarker for biologic response in severe uncontrolled CRSwNP. Further standardized, prospective studies are needed to enable personalized biologic therapy.
No takes yet. Share an insight, caveat, or question.
Alomair et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: